Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Kissei Pharmaceutical Co., Ltd.
🇯🇵
Japan
Country
🇯🇵
Japan
Ownership
Public
Established
1946-08-09
Employees
1.7K
Market Cap
-
Website
http://www.kissei.co.jp
Clinical Trials
Related News
A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Phase 3
Completed
Conditions
Spinocerebellar Degeneration
Interventions
Drug: KPS-0373, High dose
Drug: Placebo
Drug: KPS-0373, Low dose
Subscribe
First Posted Date
2013-10-25
Last Posted Date
2018-12-14
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
374
Registration Number
NCT01970098
Subscribe
A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation
Phase 2
Completed
Conditions
Chronic Constipation
Interventions
Drug: KWA-0711
Drug: Placebo
Subscribe
First Posted Date
2013-09-10
Last Posted Date
2014-11-13
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01938196
Subscribe
A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation
Phase 2
Completed
Conditions
Chronic Constipation
Interventions
Drug: KWA-0711
Subscribe
First Posted Date
2013-09-09
Last Posted Date
2014-11-13
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01937663
Subscribe
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: KCT-0809 ophthalmic solution
Drug: Placebo
Subscribe
First Posted Date
2013-07-02
Last Posted Date
2015-10-19
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01890941
Subscribe
A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
Phase 3
Completed
Conditions
Peritoneal Dialysis
Hyperphosphatemia
Interventions
Drug: PA21
Subscribe
First Posted Date
2013-05-14
Last Posted Date
2014-11-13
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01852682
Subscribe
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Phase 3
Completed
Conditions
Hyperphosphatemia
Hemodialysis
Interventions
Drug: PA21
Drug: Sevelamer hydrochloride
Subscribe
First Posted Date
2013-05-09
Last Posted Date
2018-10-09
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
213
Registration Number
NCT01850602
Subscribe
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Phase 3
Completed
Conditions
Hyperphosphatemia
Hemodialysis
Interventions
Drug: PA21
Subscribe
First Posted Date
2013-05-09
Last Posted Date
2018-10-09
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
35
Registration Number
NCT01850641
Subscribe
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Phase 3
Completed
Conditions
Hemodialysis Patients With Hyperphosphatemia
Interventions
Drug: PA21
Subscribe
First Posted Date
2013-04-17
Last Posted Date
2018-10-09
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
161
Registration Number
NCT01833494
Locations
🇯🇵
JAPAN, Multiple Locations, Japan
Subscribe
A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: KCT-0809
Drug: Placebo
Subscribe
First Posted Date
2012-09-25
Last Posted Date
2014-05-30
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01692145
Locations
🇯🇵
Japan, Tokyo and Other Japanese City, Japan
Subscribe
A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis
Phase 2
Completed
Conditions
Endometriosis
Interventions
Drug: KLH-2109
Subscribe
First Posted Date
2012-06-27
Last Posted Date
2014-05-30
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
20
Registration Number
NCT01629420
Locations
🇯🇵
Japan, Tokyo and Other Japanese City, Japan
Subscribe
Prev
1
2
3
4
5
6
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy